Author Claim Review

 Quick Explanation Copied

 Long Explanation

Career Overview and Citation Metrics

Benjamin Kasenda is a clinician-scientist in medical oncology with a productivity and impact profile that exceeds what the partial Semantic Scholar record (h-index 4, 49 citations across 26 papers) suggests. The complete OpenAlex profile shows 202 works, 5,445 total citations, and an h-index of 41, with sustained output from 2006 to 2026 and citation counts still rising (440 in 2026 to date) OpenAlex metrics for Kasenda. The large discrepancy between databases reflects incomplete author disambiguation in Semantic Scholar rather than low impact.

Most Influential Work

His highest-impact paper is a first-authored JAMA study on the prevalence and publication of discontinued randomized trials (416 citations), an influential contribution to research methodology and trial transparency JAMA discontinued trials study. This methodological thread continued with systematic reviews on recruitment failure in discontinued trials Recruitment failure review and trial cost/resource-use transparency Trial cost transparency review.

In oncology, he contributed substantially to primary CNS lymphoma (PCNSL): a first-authored individual patient data meta-analysis of elderly PCNSL patients (190 citations) Elderly PCNSL IPD meta-analysis, single-arm phase 2 trials of high-dose chemotherapy with autologous stem-cell transplantation PCNSL autologous transplant phase 2 trial, and authorship of the EANO PCNSL treatment guidelines EANO PCNSL guidelines. He also contributed to melanoma immunotherapy biomarker work (LDH as early marker under anti-PD-1 therapy, 308 citations) LDH marker in anti-PD-1 melanoma and to translational work on glycosylation-targeted immune checkpoint blockade Glycosylation and ICB study.

Current Research Direction and Assessment

Recent work (2023–2026) shows an active pivot toward adoptive cell therapy/TIL therapy in melanoma, bispecific antibodies, functional drug screening, ctDNA-guided decision-making, and evaluation of large language models in oncology decision support — the latter a forward-looking but still low-citation niche (per the supplied paper list). Strengths: methodological rigor (IPD meta-analysis, randomized trial design, including a novel randomized-invitation single-arm trial concept), guideline authorship, and translational breadth. Limitations: many recent outputs are conference abstracts with limited peer-reviewed follow-up yet, and the supplied Semantic Scholar record cannot verify full citation impact for the newest papers. Overall, Kasenda scores as a mature, methodologically careful clinical oncology researcher with genuine field leadership in PCNSL — strong, but not among the very top tier of global oncology thought leaders by citation metrics.

 BGPT Author Review

Scientific Quality

h-index 41 with 5,445 citations across 202 works, a first-authored JAMA methodology paper (416 citations), IPD meta-analyses, and EANO guideline authorship indicate a mature, rigorous clinician-scientist. Deductions: many recent outputs are conference abstracts, translational senior-author roles are less evident, and part of the citation mass is co-authored rather than independent leadership.

Communication Quality

Papers appear in high-quality, clearly written venues (JAMA, Lancet Haematology, Annals of Oncology, Neuro-Oncology) with accessible abstracts; however, evidence on direct communication quality (talks, plain-language output) is not supplied.

Author Novelty

His work is largely rigorous incremental clinical science (biomarkers, trial consolidation, guidelines), with moderate novelty in the randomized-invitation single-arm trial design and the recent LLM-in-oncology line, which is conceptually new but unproven.

Scientific Rigor

Demonstrated use of individual patient data meta-analysis, randomized phase 3 trials, systematic reviews, and explicit attention to trial discontinuation, recruitment failure, and missing-data bias signals strong methodological rigor. Some single-arm trial designs carry inherent causal-inference limits.